Chemours Co. Files 8-K: Material Agreement & Financial Obligations

TL;DR

Chemours signed a big deal and took on new financial obligations, filing an 8-K.

AI Summary

On November 29, 2024, The Chemours Company entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an off-balance sheet arrangement for the registrant. The report includes information related to Regulation FD Disclosure and Financial Statements and Exhibits.

Why It Matters

This filing signals a significant new agreement and potential financial commitments for Chemours, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and new financial obligations can introduce financial risks and operational changes that warrant close monitoring.

Key Players & Entities

• The Chemours Company (company) — Registrant
• November 29, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan
• $1,070,000,000 — able margin in respect of the Company's $1,070,000,000 senior secured U.S. dollar-denominated

Filing Documents

• cc-20241129.htm (8-K) — 54KB
• cc-ex10_1.htm (EX-10.1) — 102KB
• cc-ex99_1.htm (EX-99.1) — 18KB
• img15408389_0.jpg (GRAPHIC) — 37KB
• img172710964_0.jpg (GRAPHIC) — 35KB
• 0000950170-24-131910.txt ( ) — 444KB
• cc-20241129.xsd (EX-101.SCH) — 29KB
• cc-20241129_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. On November 29, 2024, The Chemours Company (the "Company") entered into Amendment No. 1 (the "Amendment") among the Company, certain subsidiaries of the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the "Administrative Agent"), which amends the Second Amended and Restated Credit Agreement, dated as of August 18, 2023, among the Company, the lenders from time to time party thereto and the Administrative Agent (as amended, supplemented or otherwise modified from time to time prior to November 29, 2024, the "Existing Credit Agreement"). The Amendment reduces the applicable margin in respect of the Company's $1,070,000,000 senior secured U.S. dollar-denominated term loan facility (the "Term Loan B-3 US$ Facility") from, at the election of the Company, adjusted Term SOFR + 3.50% to adjusted Term SOFR + 3.00%, or adjusted base rate plus 2.50% to adjusted base rate plus 2.00%. There are no changes to the maturity of the Term Loan B-3 US$ Facility following this repricing, and all other terms are substantially unchanged. Capitalized terms used in this Item 1.01 but not otherwise defined herein have the meanings assigned to them in the Existing Credit Agreement as amended. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

03

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated herein by reference.

01

Item 7.01 Regulation FD Disclosure. On November 29, 2024, the Company issued a press release announcing entry into the Amendment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 10.1 Amendment No. 1, dated as of November 29, 2024, among The Chemours Company, the other Loan Parties, and the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, to the Second Amended and Restated Credit Agreement dated as of August 18, 2023 Exhibit 99.1 Press release dated as of November 29, 2024 issued by the Chemours Company Exhibit 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY By: /s/ Shane Hostetter Shane Hostetter Senior Vice President, Chief Financial Officer Date: November 29, 2024

View Full Filing

View this 8-K filing on SEC EDGAR